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Objectives The goal of this study was to investigate the impact of high-dose atorvastatin on the
pharmacodynamic (PD) effects of double-dose clopidogrel in statin-naive patients with stable coro-
nary artery disease (CAD) and high-on-treatment platelet reactivity (HTPR) while on standard-dose
clopidogrel before percutaneous coronary intervention (PCI).
Background Patients with HTPR are at increased risk of adverse cardiovascular events after PCI.
High-dose statins improve prognosis in high-risk patients by lipid- and nonlipid-related mechanisms,
including antithrombotic effects.
Methods The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high
platelet activity) study was a randomized PD study of high-dose (80 mg) atorvastatin in addition to
double-dose (150 mg) clopidogrel (atorvastatin group, n  38) versus double-dose clopidogrel alone
(control group, n  38) in patients with HTPR. HTPR was deﬁned as P2Y12 reaction units (PRU) 235
y the VerifyNow P2Y12 assay. Platelet reactivity was evaluated immediately before PCI and at 10
nd 30 days.
esults Patients randomized to atorvastatin had lower PRU values (188  48 vs. 223  53 PRU, p 
.01; primary endpoint) and HTPR rates (16% vs. 42%, p  0.01) at 30 days than patients in the con-
rol group. Statin treatment (odds ratio [OR]: 3.8, p  0.011), baseline PRU 298 (OR: 10.7, p 
.0001), noncarrier status of CYP2C19*2 loss-of-function allele (OR: 2.9, p  0.043), and age (OR: 0.94,
 0.032) were variables signiﬁcantly associated with optimal PD response (PRU 235) at 30 days.
o correlations were found between PRU and lipid fractions.
onclusions High-dose atorvastatin signiﬁcantly improved the PD effects of double-dose clopi-
ogrel in our stable CAD patients with HTPR undergoing PCI (Atorvastatin and Clopidogrel HIgh
Ose in stable patients with residual high platelet activity [ACHIDO]; NCT01335048). (J Am Coll
ardiol Intv 2013;6:169–79) © 2013 by the American College of Cardiology Foundation
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170The long-term prognostic benefits of 3-hydroxy-3-methyl glu-
taryl coenzyme A reductase inhibitors in high-risk patients are
well established, and their use is strongly recommended for
secondary prevention in patients with coronary artery disease
(CAD) (1). The clinical benefit of statins is attributed to multiple
mechanisms that go beyond their lipid-lowering effects and
include antithrombotic properties (2). In fact, statins inhibit
adenosine diphosphate (ADP) and thrombin-induced platelet
aggregation in both healthy subjects and patients with CAD (3,4).
Although a pharmacodynamic (PD) interaction between clopi-
dogrel and cytochrome CYP3A4–metabolized statins has been
described in the acute phase of clopidogrel treatment with stan-
dard loading-dose regimens (5,6), most studies show a lack of
nteraction that has been consistently shown when using high
lopidogrel dosing regimens as well as once patients are in the
maintenance phase of treatment
(7–11). Moreover, PD studies ap-
pear to show some synergy between
clopidogrel and atorvastatin (3,4).
Atorvastatin effects seem to be dose
related and additive to that exerted
by clopidogrel (4).
See page 180
High on-treatment platelet reac-
tivity (HTPR) has been shown to
be an independent risk factor for
recurrent ischemic events, particu-
larly in patients undergoing per-
cutaneous coronary intervention
(PCI) (12). Double maintenance
doses of clopidogrel may be a pos-
sible strategy to overcome HTPR
(13–15). However, the impact of
this treatment, when used in asso-
ciation with high-dose atorvastatin,
has not been explored. The aim of
this prospective, randomized study
was to evaluate the effects of high-dose (80 mg/day) atorvastatin
on PD profiles of double-dose clopidogrel (150 mg/day) in
statin-naive patients with stable CAD and HTPR undergoing
PCI.
Methods
Population and study protocol. The ACHIDO (Atorvasta-
in and Clopidogrel HIgh DOse in stable patients with
The Medicines Company, Portola, Accumetrics, Schering-Plough, AstraZeneca,
Eisai, Bristol-Myers Squibb, and Sanofi-Aventis. Dr. Marcucci has received hono-
raria for lectures from Daiichi Sankyo, Eli Lilly & Co., and Merck Sharp & Dohme.
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
BASE  iso-thrombin
receptor activating peptide
reaction unit
CAD  coronary artery
disease
CI  confidence interval
CK-MB  creatine kinase
MB fraction
HTPR  high-on-treatment
platelet reactivity
IPA  percent P2Y12
inhibition
iso-TRAP  iso-thrombin
receptor activating peptide
OR  odds ratio
PCI  percutaneous
coronary intervention
PD  pharmacodynamic
PRU  P2Y12 reaction units
ULN  upper limit of normalDr. Abbate has received consulting fees from Eli Lilly & Co.; lecture fees from
Instrumentation Laboratory and Sigma Tau; and research grant funding from Bayer, aesidual high platelet activity) study was a prospective,
andomized, active-control, PD trial. From April 2011 to
ecember 2011, all consecutive statin-naive patients (N 
09) with angiographically documented CAD undergoing
CI with stent implantation at the Division of Cardiology,
isericordia e Dolce Hospital (Prato, Italy) were consid-
red for enrollment in the present study. Per our institu-
ional protocol, all stable patients scheduled to undergo
lective angiography are prescribed with aspirin (100 mg/day)
nd clopidogrel (600 mg loading dose followed by a main-
enance dose of 75 mg/day) for at least 7 days. Exclusion
riteria included: contraindications to statin treatment;
cute renal failure or end-stage renal failure requiring
ialysis; active liver disease or liver cirrhosis; unexplained
ransaminase increase 2 times the upper limit of normal
ULN); peripheral muscle disease or creatine kinase 2.5
imes ULN; treatment with a glycoprotein IIb/IIIa inhibitor
ithin the past week; current treatment with proton-pump
nhibitors and/or omega-3; active bleeding or recent bleed-
ng diathesis (within the past month); platelet function
isorder or platelet count150 103/l; hemoglobin10
/dl; need for warfarin treatment; previous hemorrhagic
troke; malignancy; and refusal of consent. Of the 209
atients screened for the study, 90 (43%) presented HTPR
mmediately before PCI. HTPR was defined as P2Y12
reaction units (PRU) 235 according to the VerifyNow
P2Y12 platelet function test (Accumetrics, San Diego,
California) (16–19). Of these, 12 had exclusion criteria, and
thus a total of 78 patients were enrolled in this study.
Patient disposition is summarized in Figure 1. Per study
protocol, all enrolled patients were treated with a double
maintenance dose of clopidogrel (150 mg/day). This regi-
men was chosen, given its efficacy in reducing platelet
reactivity in patients with HTPR as observed in other PD
investigations (13–15). More potent treatment strategies in
overcoming HTPR, such as by the novel P2Y12 receptor
inhibitors prasugrel or ticagrelor, were not considered since
these drugs have an indication for use only in the setting of
acute coronary syndromes, and our population was com-
posed of stable CAD patients.
Randomization (1:1) to the atorvastatin or control arms
was performed immediately after PCI by computerized
open-label assignments in consecutive blinded envelopes: 39
patients were assigned to receive clopidogrel at the
maintenance dose of 150 mg/day (8 AM) and atorvastatin
80 mg/day (10 PM) (atorvastatin group) and 39 patients to
receive only clopidogrel at 150 mg/day (control group).
Antiplatelet and statin regimens were maintained un-
oehringer Ingelheim, and Pfizer. All other authors have reported that they have no
elationships relevant to the contents of this paper to disclose.
anuscript received May 24, 2012; revised manuscript received August 30, 2012,
ccepted September 12, 2012.
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171changed for 30 days. One patient in the atorvastatin
group and 1 in the control group withdrew from the study
due to drug intolerance. Thus, 76 patients completed the
study.
All patients continued treatment with aspirin (100 mg/
day) indefinitely. At the end of the study, the choice of
antiplatelet and statin dosage was left at the discretion of the
treating physician. PCI was performed according to current
standard guidelines; the type of stent implanted and the
periprocedural use of antithrombotic therapy, including
glycoprotein IIb/IIIa inhibitor use and choice of anticoag-
Statin naïve patients with stable C
Aspirin (100 mg/day) + Clopi
n = 2
Randomiz
Assigned to 
Clopidogrel 150 mg/day 
n = 39 
Pre-PCI Verify N
Patients eligible
n= 9
1 patient  
Clopidogrel intolerance 
Completed study  
n = 38 
Patients with pre-PCI PRU < 235 
n = 119 
10th day-Verify
Clinical follow-up a
30th day-Verify
Clinical follow-up a
Figure 1. Study Flow Chart
Enrollment criteria and trial ﬂow. CAD  coronary artery disease; PCI  percutulant, were left to the discretion of the operator.Periprocedural myocardial infarction was defined as cre-
atine kinase-MB (CK-MB) mass elevation 3 times ULN
within 24 h after PCI or the development of new Q waves
in 2 or more contiguous electrocardiographic leads with
CK-MB greater than ULN (1).
Clinical, biochemical, angiographic, and genotyping data
were recorded for all patients in a dedicated database. The
protocol was approved by our institutional ethics commit-
tee, and all patients gave written informed consent.
Platelet reactivity. Platelet reactivity was evaluated immedi-
ately before PCI (T-0) and at 10 (T-1) and 30 (T-2) days
ndidates for PCI with stent 
l 75 mg/day pretreated 
12 patients excluded for: 
- contraindication to statins n = 4 
- need for warfarin treatment n = 2 
- end stage renal disease n = 1 
- known myopathy = 2 
- malignancy = 1 
- informed refusal of consent n = 2
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172measures the inhibition of P2Y12 ADP receptors on plate-
lets. Technical details of the assay have been described
previously (20). Blood samples for platelet function testing
were collected just before PCI and 2 to 4 h after the
ingestion of the last clopidogrel dose. We note that the first
blood sample (T-0) was drawn before administration of
glycoprotein IIb/IIIa inhibitors. The VerifyNow instrument
reports 3 different parameters for each assay: 1) PRU, which
express the extent of ADP-mediated aggregation specific to
the P2Y12 receptors; 2) iso-TRAP reaction units (BASE)
which represents total platelet function, despite P2Y12
receptor blockage, in response to iso-thrombin receptor
activating peptides (iso-TRAP) specific to the thrombin
protease-activated receptor-1 (PAR-1) and PARS-4; and 3)
percent platelet P2Y12 inhibition (IPA) calculated based on
he PRU and BASE results according to the formula:
(BASE  PRU)  BASE]  100 (20). We calculated
absolute and relative changes over time in PRU and BASE
values. The quality controls for our laboratory have been
reported elsewhere (18). Clinical follow-up and plasma lipid
levels were also carried out at T-0, T-1, and T-2. Compli-
ance and adverse events were assessed by the attending
physician based on interview, pill count, and laboratory
evaluation.
Genotyping. Genomic DNA was isolated from venous pe-
ipheral blood using Tecan, Freedom EVO liquid handler
Tecan Group, Männedorf, Switzerland) and the magnetic
ead based GeneCatcher gDNA Blood kit (Invitrogen,
arlsbad, California). DNA purity and concentration were
etermined by NanoDrop spectrophotometer (Thermo
cientific, Wilmington, Delaware). Genotyping of the
YP2C19*2 loss-of-function polymorphism (681G  A,
s4244285) was performed using TaqMan validated Drug
etabolism Genotyping assay with the 7900HT Sequence
etection System (Applied Biosystems, Foster City, Cali-
ornia) (21).
Study endpoints and sample size calculation. The primary
endpoint of the study was the PRU after 30 days (T-2) of
treatment. The sample size was calculated by assuming
mean baseline PRU values of 285  47 in patients with
HTPR, defined as PRU 235 while on standard-dose
clopidogrel, and a mean PRU reduction of 24% after 30
days of 150-mg clopidogrel (15). Thus, 74 patients were
required (37 per treatment group) to detect a further 15%
relative reduction in mean PRU values in the atorvastatin
compared with the control group, with 80% power at the
conventional, 2-sided significance level of 5%. Our protocol
required that each group comprise at least 39 patients to
allow a 5% dropout rate. Additional exploratory endpoints
were: 1) the percentage of patients with optimal response at
30 days, defined as PRU 235; 2) the changes over time in
PRU and BASE; and 3) correlations with lipid levels.
Statistical analysis. Variables were analyzed for a normal
distribution with the Kolmogorov-Smirnov test, and vari-ables are presented as mean  SD or as median (interquar-
tile range). Categorical variables were presented as counts
and percentages, and compared by chi-square or Fisher
exact test. Continuous variables were compared by t test for
normally distributed values; the Mann-Whitney U test was
used alternatively. The repeated-measure analysis of vari-
ance was used to evaluate platelet reactivity and lipid
fraction changes over time. Pairwise comparisons within
group were approached with t test for paired samples and
onferroni adjustment (yielding a significance threshold of
.016). The Pearson correlation coefficient was used to
easure the relationship between PRU and BASE and lipid
raction values. The univariate analysis was used to identify
he variables significantly associated with optimal response
PRU 235) at 30 days. For baseline PRU values, the
ptimal cutoff values were calculated by receiver-operating
haracteristic curve analysis as the closest to the upper-left
orner. The association with optimal response at 30 days
as expressed as the odds ratio (OR), and the 95% confi-
ence interval (CI) was also reported. All p values are
-tailed, and statistical significance was defined as p 0.05.
ll analyses were performed with SPSS statistical software,
ersion 19.0 (SPSS, Chicago, Illinois).
esults
The mean age for the entire study cohort was 67  11 years,
and 43% of patients were over 70 years old. Forty-two percent
of patients had estimated creatinine clearance 60 mL/min,
6% had diabetes mellitus, and 64% multivessel coronary
isease. Clinical, biochemical, and procedural variables were
omparable in the 2 treatment arms. In particular, advanced
ge, diabetes mellitus, poor renal function, and higher total
holesterol levels were evenly distributed in the 2 groups. No
ignificant differences were observed in CYP2C19*2 loss-of-
unction allele frequencies (Table 1).
Platelet reactivity. The mean time intervals between the
oading dose of clopidogrel and T-0 were 10  3 and 10  2
ays in the atorvastatin and control groups, respectively (p 
.68). All patients enrolled in the study underwent all the PD
esting as scheduled, and the time intervals were similar for
oth groups (Table 2). Results of platelet reactivity at each time
oint for both groups are presented in Table 2. The PRU
alues decreased significantly from baseline to 10 days and
rom baseline to 30 days in both treatment arms. However,
atients in the atorvastatin group achieved significantly lower
RU than patients in the control group at 30 days (188 48 vs.
23  53, respectively; p  0.01; primary endpoint).
The distribution of mean PRU values over time in both
groups is shown in Figure 2A. PRU values in the atorvas-
tatin group decreased consistently for 30 days, whereas in
the control group, PRU values showed a marked reduction
in the first 10 days and a slight increase thereafter. The
extent of relative PRU reduction mirrors this trend over
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173Table 1. Clinical Characteristics, and Biological and Angiographic Parameters of the Study Groups
Atorvastatin Group (n  38) Control Group (n  38) p Value
Age, yrs 66 11 68 11 0.58
Age 70 yrs 16 (42) 17 (45) 0.82
Men 30 (79) 27 (71) 0.59
Risk factors
Hypertension 24 (63) 29 (76) 0.31
Diabetes mellitus 12 (32) 15 (39) 0.63
Active smoking 14 (37) 9 (24) 0.31
BMI, kg/m2 26 [24–29] 28 [25–30] 0.23
Total cholesterol 200 mg/dl 11 (29) 10 (26) 1.00
Creatinine clearance 60 ml/min 16 (42) 16 (42) 1.00
Previous MI 9 (24) 9 (24) 1.00
Previous PCI or CABG 10 (26) 9 (24) 1.00
Baseline LV ejection fraction, % 51 10 54 5 0.07
Laboratory variables
Hemoglobin, mg/dl 13.9 0.9 13.6 1 0.15
RBCs, 103/l 46 0.5 4.5 0.3 0.44
WBCs, 103/l 6.6 1.7 6.8 1.8 0.74
Platelet count, 103/l 203 51 208 48 0.61
MPV, 109/l 9 1 9 1 0.84
hs-CRP, mg/l 0.28 0.5 0.24 0.2 0.52
Creatinine clearance, ml/min 67 18 66 22 0.83
Baseline cTnI, ng/ml 0.03 0.04 0.02 0.03 0.14
Baseline CK-MB, ng/ml 2.4 1.1 2.3 0.8 0.74
Angiographic and PCI data
Multivessel disease 26 (68) 23 (61) 0.63
Multivessel PCI 17 (45) 14 (37) 0.64
Lesion location 0.82
Left anterior descending 21 (37) 19 (35)
Left circumﬂex artery 17 (30) 17 (31)
Right coronary artery 16 (28) 17 (31)
Left main 2 (4) 1 (2)
Saphenous vein graft 1 (2) 0
Mean number of stents 2.5 1.3 2.5 1.6 0.93
Total stent length, mm 47 28 44 25 0.63
Stent type 0.51
Drug-eluting stents 31 (82) 34 (89)
Bare-metal stents 7 (18) 4 (11)
GP IIb/IIIa inhibitor* 13 (34) 9 (24) 0.44
CYP2C19*2 polymorphism genotype
*1*1 27 (71) 27 (71) 1.00
*1*2 9 (24) 10 (26)
*2*2 2 (5) 1 (3)
Concomitant medications at T-0
Beta-blockers 20 (51) 15 (41) 0.35
Calcium channel blockers 8 (21) 6 (16) 0.76
ACE inhibitors 24 (64) 20 (54) 0.49
ARB 4 (10) 5 (13) 0.99
Nitrates 10 (26) 12 (31) 0.80
Diuretic 6 (15) 3 (10) 0.47
Insulin 4 (10) 4 (10) 1.00
Values are mean SD n(%), or median [interquartile range]. *Only eptifibatide was used.
ACE angiotensin-converting enzyme; ARB angiotensin II receptor blockers; BMI body mass index; CABG coronary artery bypass graft;
CK-MB  creation kinase-MB; cTnI  cardiac troponin I; GP  glycoprotein; hs-CRP  high sensitivity C-reactive protein; LV  left ventricular;
WBCwhite blood cell; MImyocardial infarction; MPVmean platelet volume; PCI percutaneous coronary intervention; RBC red blood cell;T-0 enrollment time.
 P2Y
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174time, and the difference between the 2 groups becomes
significant only at 30 days (35  16% vs. 23  16%, p 
0.01) (Table 2, Fig. 2B). Iso-TRAP–mediated platelet
reactivity, expressed by BASE values, decreased slightly over
time in the control group. Atorvastatin-treated patients
showed a distinctive pattern of BASE reduction with a
significant marked decrease in the short term (T-1) and a
later increase (T-2) to levels similar to that of controls
(Table 2, Fig. 3). Based on the results of PRU and BASE,
the mean IPA was significantly higher after 1 month of
treatment with atorvastatin (37  14% vs. 28  15%,
respectively; p  0.01) (Table 2).
Table 2. Distribution of Platelet Function Parameters
Atorvastat
T-0 T-1
Time to determination, days 11 2
PRU 290 35 200 5
Absolute difference from T-0 90 5
Relative difference from T-0, % 31 1
Absolute difference from T-1
Relative difference from T-1, %
BASE 312 39 290 3
Absolute difference from T-0 23 2
Relative difference from T-0, % 7 8
Absolute difference from T-1
Relative difference from T-1, %
IPA, % 8 7 31 1
Values aremean SD. *p 0.01 versus baseline (T-0);†p 0.01within
BASE iso-TRAP reaction units; IPA percent P2Y12 inhibition; PRU
150
200
250
300
T-0 T-1 T-2
Cl
At
P = 0.35 P =  0.004
A
Figure 2. Differences in ADP-Induced Platelet Reactivity as Expressed by P
(A) Mean P2Y12 reaction units (PRU) values at baseline (T-0), 10 days (T-1) and
mg patients (circles). (B) Differences in mean relative PRU reduction from T-0
dogrel 150 mg patients are gray. ADP  adenosine diphosphate.High residual platelet reactivity. A higher number, albeit
not significant, of patients randomized to atorvastatin
changed their response status, becoming optimal responders
at T-1 (10 days) compared with patients in the control arm
(74% vs. 63%, p  0.1). This number further increased at
T-2 (30 days), reaching statistical significance (84% vs. 58%,
p  0.02) (Fig. 4). Baseline variables significantly associated
with 30-day optimal response at univariate analysis included age
(OR: 0.94 [95% CI: 0.89 to 0.99]; p  0.032), noncarrier status
of the CYP2C19*2 allele (OR: 2.9 [95% CI: 1.01 to 8.39]; p 
0.043), baseline higher PRU values (OR: 0.98 [95% CI: 0.96 to
0.99]; p 0.005), and use of atorvastatin (OR: 3.8 [95% CI: 1.3
Study Time Course
up Control Group
T-2 T-0 T-1 T-2
32 4 10 1 32 4
188 48*†‡ 292 37 210 58* 223 53*†
102 54‡ 82 53 69 51
35 16‡ 28 17 23 16
12 35‡ 13 49
4 20‡ 12 31
298 34† 316 29 313 37 310 20
14 46 3 34 6 30
3 13 1 11 1 9
9 35 3 30
4 12 0.05 10
37 14*†‡ 10 7 33 16* 28 15*†
(Bonferroni adjustment);‡p 0.01 atorvastatin versus control group.
12 reaction units.
ogrel 150
statin+Clopidogrel 150
-50
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175to 11.5]; p  0.011), (Table 3). The receiver-operating charac-
eristic curve analysis showed that pre-procedural PRU signifi-
antly discriminate between patients with and without HTPR at
0 days, with an area under the curve of 0.77 (95% CI: 0.6 to 0.9,
 0.001). A PRU value 298 was identified as the optimal
utoff point to predict optimal response at 30 days (OR: 10.7 [95%
I: 3.3 to 34.8]; p  0.0001).
Lipid levels. Patients treated with high-dose atorvastatin showed
a significant reduction in all fractions of cholesterol and triglycer-
ides at 10 and 30 days. In particular, low-density lipoprotein
cholesterol levels were markedly lower in patients randomized to
250
280
310
340
T-0 T-1 T-2
P = 0.09P = 0.004
A
Figure 3. Differences in iso-TRAP–Induced Platelet Reactivity as Expressed
(A) Mean iso-thrombin receptor activating peptide (iso-TRAP) reaction unit (BA
clopidogrel 150 mg (squares) and clopidogrel 150 mg patients (circles). (B) D
atorvastatinclopidogrel 150 mg is indicated by the red, and clopidogrel 150
Figure 4. Responsiveness Status at 10 and 30 Days
Responsiveness status at 10 days (T-1) and 30 days (T-2). P2Y12 reaction units
the red, and PRU values 235 (optimal responders) by the blue. Continuous
patients who change their reactivity between T-1 and T-2. Responsiveness status attreatment with atorvastatin at both time points (Table 4). How-
ever, no significant correlations were found between the different
lipid fractions and PRU and BASE values.
Adverse events and follow-up. Clinical follow-up was com-
pleted in all patients. Overall, the occurrence of periprocedural
myocardial infarction was 18%, without significant differences
between the 2 groups (atorvastatin, 16%, vs. control, 21%, p
0.7); the mean peak CK-MB values were 7  8 ng/ml versus
10  17 ng/ml in the atorvastatin and control groups,
respectively (p  0.2). No other ischemic events, major
bleeding, or transfusions were reported during the follow-up.
Clopidogrel 150
Atorvastatin+Clopidogrel 150
-12
-7
-2
3
T-1 vs T-0 T-2 vs T-0
P = 0.004 P = 0.5
B
ASE
lues at baseline (T-0), 10 days (T-1), and 30 days (T-2) in atorvastatin
ces in mean relative BASE reduction from T-0 to T-1 and from T-0 to T-2:
y the gray.
values 235 (high on-treatment platelet reactivity [HTPR]) are indicated by
show patients with stable reactivity between T-1 and T-2. Arrows indicateby B
SE) va
ifferen(PRU)
linesbaseline is not represented: all patients had PRU values 235.
er abbr
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176At 30 days, 2 patients, both randomized to atorvastatin,
presented a transaminase increase 2  ULN.
Discussion
The results of this prospective, PD, randomized study show
that treatment with high-dose atorvastatin associated with
double-dose clopidogrel reduces platelet reactivity signifi-
cantly more than double-dose clopidogrel alone in statin-
Table 3. Univariate Analysis of Predictors of Clopidog
Optimal Resp
(n
Age, yrs 6
Age 70 yrs 20
Male 41
Diabetes mellitus 16
Hypertension 38
BMI, kg/m2 26
Laboratory variables
Hemoglobin, mg/dl 13
RBCs, 103/l 4
WBCs, 103/l 6
Platelet count, 103/l 21
MPV, 109/l 9
Creatinine clearance, ml/min 6
hs-CRP, mg/l 0.2
Creatinine clearance 60 ml/min 20
Baseline LV ejection fraction, % 5
CYP2C19*2 polymorphism genotype
*1*1 42
*1*2 12
*2*2
Allocation to high-dose atorvastatin 32
Total cholesterol, mg/dl 18
LDL-cholesterol, mg/dl 11
HDL-cholesterol, mg/dl 4
Triglycerides, mg/dl 12
Baseline (T-0) PRU 28
Baseline (T-0) BASE 31
Values are mean SD, n(%), or median [interquartile range]. *Values
HDL high-density lipoprotein; LDL low-density lipoprotein; oth
Table 4. Change in Lipid Profile Over Time in Atorvas
Atorvastatin Gr
T-0 T-1
Total cholesterol, mg/dl 183 42 146 38*†
LDL-cholesterol, mg/dl 117 34 91 30*†
HDL-cholesterol, mg/dl 40 8 35 8*
Triglycerides, mg/dl 127 54 95 39*†
Values aremean SD. *p 0.01 versus baseline (T-0);†p 0.01 atorvAbbreviations as in Table 3.naive patients with stable CAD and HTPR before PCI. In
particular, the antiplatelet effects of high-dose atorvastatin
occur early and persist over time; they are additive to those
of clopidogrel and do not correlate with the degree of lipid
reduction observed during the study period.
Statins are known to have multiple nonlipid-lowering
(“pleiotropic”) effects. They have vasoprotective, anti-
inflammatory, antioxidant, immunomodulating properties,
and also inhibit platelet function (2). In particular, statins
esponse at 30 Days
(Pry <235)
)
HTPR (Pry >235)
(n  22) p Value
72 10 0.027
13 (59) 0.08
16 (73) 0.77
11 (50) 0.09
15 (68) 0.84
] 27 [25–29] 0.26
13.7 1 0.74
4 4.6 0.3 0.99
9 6.4 1.3 0.38
196 45 0.33
4 9.3 1.1 0.53
60 18 0.12
6 0.31 0.4 0.45
12 (55) 0.16
55 6 0.21
0.008*
12 (55)
7 (32)
3 (14)
6 (27.3) 0.02
181 34 0.90
116 35 0.83
37 8 0.32
139 63 0.33
311 29 0.002
313 32 0.87
mpared using the p for trend test.
eviations as in Table 1.
and Control Group
Control Group
T-2 T-0 T-1 T-2
4 24*†‡ 181 28 170 33 165 39*‡
1 17*†‡ 117 29 109 29 105 37‡
6 10*‡ 38 10 35 9 36 8
8 34*†‡ 127 55 132 61 119 55
ersus control group;‡p 0.01within group (Bonferroni adjustment).rel R
onders
 54
5 11
(37)
(76)
(30)
(70)
[24–29
.8 1
.5 0.
.8 1.
0 51
.5 1.
9 20
4 0.
(37)
2 9
(78)
(22)
—
(59.3)
2 36
8 1
0 9
4 55
3 35
4 35
were cotatin
oup
13
8
3
8
astatin v
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177have been shown to reduce platelet aggregation, dense
granule release, and platelet-mediated thrombus formation,
all rapidly and in a dose-dependent manner (3,4,22,23).
Moreover, the combination of standard-dose clopidogrel
(75 mg) with atorvastatin (40 mg), leads to further reduc-
tion in ADP- and TRAP-induced platelet activation and
TRAP-induced platelet aggregation (4). This additive effect
is already evident with low-dose (20 mg) atorvastatin and
persists over time (3). Although PD interaction between
clopidogrel and atorvastatin, both substrates of cytochrome
CYP3A4, has been described in the early phase of clopi-
dogrel treatment (standard loading dose) (5,6), a lack of PD
interaction has been shown with high clopidogrel doses as
well as once patients are in the maintenance phase of
treatment, which was the setting of our study (7–11).
Our study expands upon previous data showing that the
addition of high-dose atorvastatin (80 mg) in statin-naive
HTPR patients simultaneously with increased doses of
clopidogrel (150 mg) is associated with enhanced platelet
inhibitory effects, in particular with more potent P2Y12
receptor inhibition at 30 days compared with controls. The
reduction of ADP-mediated reactivity is greater in our study
than in previous studies that showed minimal effect on
ADP-induced aggregation (4). This could depend on vari-
ous factors, including the very high dose (80 mg) of
atorvastatin administered in our study, the relatively low
efficacy of high-dose clopidogrel in HTPR patients, and/or
the synergy in inhibition of ADP-mediated and iso-TRAP–
mediated platelet aggregation pathways (24). In fact, only
atorvastatin-treated patients had significant early inhibition
of iso-TRAP–-induced aggregation. This effect is less
appreciated at 30 days when the values of BASE were
similar in the 2 study groups. We could assume that in the
early period following PCI, when thrombin levels increase,
atorvastatin exerts a protective role (17) as supported by the
inhibition of iso-TRAP–mediated aggregation.
Our series of stable CAD patients, undergoing PCI and
treated with clopidogrel (75 mg) for at least 7 days,
presented a relatively high incidence (43%) of HTPR, but
overall consistent with other studies (25). This could be due
to the advanced age and high prevalence of diabetes mellitus
and renal dysfunction in our study population, all clinical
factors associated with HTPR (13,26,27). The association
of high-dose atorvastatin and double-dose clopidogrel in the
present study significantly reduced 30-day HTPR rates
compared with clopidogrel 150 mg alone (16% vs. 42%, p
0.02). We note that the percentage of 30-day optimal
responder patients attributable to high-dose atorvastatin
(	26%) was similar to that reported with the switch to a
non–CYP3A4-metabolized statin (	24%) in stable patients
with HTPR while on chronic coadministration of low-dose
(10 mg) atorvastatin and standard-dose clopidogrel in the
ACCEL-STATIN (Accelerated Platelet Inhibition by
Switching From Atorvastatin to a Non-CYP3A4-Metabolized Statin in Patients With High Platelet Reac-
tivity) study (28). The 2 studies were different for design,
clinical and genetic characteristics of patient populations,
and strategy: in this ACHIDO study, high-dose atorvasta-
tin was added in separate administration (atorvastatin 10
PM, clopidogrel 8 AM) to double-dose clopidogrel in statin-
naive HTPR patients already on clopidogrel (75 mg).
The minimal impact on HTPR with only 150-mg clopi-
dogrel is consistent with findings of other studies
(13,15,29). Furthermore, similar to previous studies using
standard (75 mg) maintenance dose of clopidogrel, this
study shows a temporal variability in platelet reactivity even
with 150-mg clopidogrel (30). The late slight increase of
PRU values (from T-1 to T-2) in the control group may be
due to the metabolic adaptation to the higher dose of
clopidogrel. This effect does not take place in the atorvas-
tatin group as reflected in the further increase in the number
of optimal responders at T-2. This may have clinical
relevance because prior investigations show that the predic-
tive value of platelet reactivity was higher when evaluated 30
days after PCI (30).
Age, carrier status of CYP2C19*2 loss-of-function allele
and higher PRU values are the baseline clinical character-
istics associated with HTPR at 30 days. Baseline high PRU
values (298) are the most powerful covariate and indicate
the possibility for early identification of risk of persistent
high nonresponse even to higher doses of clopidogrel
(15,31). We must also point out that treatment with
high-dose atorvastatin had a predictive value similar to that
of noncarrier status of CYP2C19*2 loss-of-function allele in
this study.
To date, the exact biological mechanisms involved in the
statin modulation of platelet function are not fully under-
stood. Both lipid-lowering and nonlipid-related effects
probably contribute, because patients with hypercholester-
olemia have hyperreactive platelets that may normalize after
lipid-lowering treatment (32). By contrast, statins have
antithrombotic effects through mechanisms that are preva-
lently cholesterol independent (33). In this study, high-dose
atorvastatin significantly decreased lipid levels with a pattern
similar to that of decreasing PRU values. However, we did
not find any correlations between lipid fractions and PRU
and BASE values, suggesting that atorvastatin may also
have nonlipid-related antithrombotic mechanisms.
The clinical implications of our study can only be spec-
ulative. Larger randomized clinical studies are needed to
define whether the significant enhancement of clopidogrel
antiplatelet activity exerted by high-dose atorvastatin may
provide biological support for a beneficial impact on out-
come in patients with HTPR undergoing PCI. The lack of
clinical benefits with high-dose conventional antiplatelet
therapy (e.g., GRAVITAS [Gauging Responsiveness With
A VerifyNow Assay–Impact on Thrombosis And Safety]
study) currently does not support such a therapeutic strategy
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178in patients with stable CAD and HTPR identified by a
single function test (25). We also know that regardless of
PD results, ample clinical studies have shown better cardio-
vascular outcomes in patients treated with clopidogrel and
statin compared with those who received clopidogrel alone,
independent of the type of statin administered (CYP3A4-
or non–CYP3A4-metabolized statin) (34). These results
suggest that improved outcome with statins in patients
treated with clopidogrel is due to more than platelet
inhibition.
Study limitations. First, only the VerifyNow P2Y12 assay
was used to evaluate platelet function. Second, it had an
open-label design, although platelet reactivity and genotyp-
ing were blindly evaluated. Third, the small sample size does
not allow definitive conclusions about the biological link
between platelet reactivity and achieved lipid levels. Fourth,
we only looked for the CYP2C19*2 polymorphism due to its
consistent association with poor clopidogrel metabolizing
status and clopidogrel response. Indeed, other polymor-
phisms could have been considered (e.g., CYP3A4/5,
ABCB1); however, PD studies have found inconsistent
association with clopidogrel response (35). Finally, given the
pilot nature of this study, it was not designed to evaluate
clinical outcomes, which would require larger populations.
Conclusions
In stable CAD patients with HTPR undergoing PCI, the
addition of high-dose atorvastatin for 30 days significantly
improves the pharmacodynamic effects of high-dose clopi-
dogrel and is associated with improved rates optimal clopi-
dogrel response. Further studies are necessary to demon-
strate the clinical impact of this strategy.
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